"\u0646\u0648\u0641\u0627\u0641\u0627\u0643\u0633 (\u0628\u0627\u0644\u0625\u0646\u062C\u0644\u064A\u0632\u064A\u0629: Novavax)\u200F \u0647\u064A \u0634\u0631\u0643\u0629 \u0623\u0645\u0631\u064A\u0643\u064A\u0629 \u062A\u0642\u0648\u0645 \u0628\u062A\u0637\u0648\u064A\u0631 \u0644\u0642\u0627\u062D\u0627\u062A \u0636\u062F \u0627\u0644\u0623\u0645\u0631\u0627\u0636.\u064A\u0642\u0639 \u0645\u0642\u0631\u0647\u0627 \u0627\u0644\u0631\u0626\u064A\u0633\u064A \u0641\u064A \u063A\u0627\u064A\u062B\u0631\u0633\u0628\u064A\u0631\u063A \u060C\u0645\u064A\u0631\u064A\u0644\u0627\u0646\u062F \u0648\u062A\u0645\u062A\u0644\u0643 \u0645\u0646\u0634\u0622\u062A \u0641\u064A \u0645\u062F\u064A\u0646\u0629 \u0631\u0648\u0643\u0641\u064A\u0644 \u0648\u0645\u062F\u064A\u0646\u0629 \u0623\u0648\u0628\u0633\u0627\u0644\u0627 \u0641\u064A \u0627\u0644\u0633\u0648\u064A\u062F."@ar . . . . . . "Novavax"@en . . . . . . "\uB178\uBC14\uBC31\uC2A4"@ko . . . . "Novavax, Inc. adalah sebuah perusahaan pengembangan vaksin Amerika Serikat yang bermarkas besar di Gaithersburg, Maryland, dengan fasilitas-fasilitas tambahan di Rockville, Maryland dan Uppsala, Swedia. Pada 2020, perusahaan tersebut menjalani pengujian klinis Tahap III terhadap orang-orang dewasa untuk vaksin kandidatnya untuk , NanoFlu dan vaksin kandidat untuk pencegahan COVID-19."@in . "Novavax \u00E9s una empresa nord-americana de desenvolupament de vacunes amb seu a Gaithersburg, Maryland, amb instal\u00B7lacions addicionals a Rockville, Maryland i Uppsala, Su\u00E8cia. Des del 2020, tenia un assaig cl\u00EDnic de fase III en curs en adults majors per a la vacuna candidata contra la grip estacional, NanoFlu i una vacuna candidata contra la COVID-19 (NVX-CoV2373)."@ca . . "\u8BFA\u74E6\u74E6\u514B\u65AF\u533B\u836F"@zh . . . "\uB178\uBC14\uBC31\uC2A4 \uC8FC\uC2DD\uD68C\uC0AC(Novavax, Inc.)\uB294 \uBBF8\uAD6D \uBA54\uB9B4\uB79C\uB4DC\uC8FC\uC5D0 \uBCF8\uC0AC\uB97C \uB454 \uBC31\uC2E0 \uAC1C\uBC1C \uD68C\uC0AC\uB85C, \uC2EC\uAC01\uD55C \uAC10\uC5FC\uBCD1\uC5D0 \uB300\uC751\uD558\uAE30 \uC704\uD55C \uD601\uC2E0\uC801\uC778 \uBC31\uC2E0\uC744 \uB9CC\uB4DC\uB294 \uC0DD\uBA85 \uACF5\uD559 \uD68C\uC0AC(biotechnology company)\uC774\uB2E4."@ko . "U.S."@en . . "Novavax"@cs . . . . . . "Novavax \u00E9s una empresa nord-americana de desenvolupament de vacunes amb seu a Gaithersburg, Maryland, amb instal\u00B7lacions addicionals a Rockville, Maryland i Uppsala, Su\u00E8cia. Des del 2020, tenia un assaig cl\u00EDnic de fase III en curs en adults majors per a la vacuna candidata contra la grip estacional, NanoFlu i una vacuna candidata contra la COVID-19 (NVX-CoV2373)."@ca . . "NVAX"@en . . . . . . . . . . . "Novavax ist ein US-amerikanisches Pharmaunternehmen, das auf die Entwicklung von Impfstoffen spezialisiert ist. Es hat seinen Hauptsitz in Gaithersburg in Maryland und zus\u00E4tzliche Einrichtungen in Rockville (Maryland) und Uppsala (Schweden). Novavax ist an der NASDAQ gelistet."@de . . . . . . . . . . . "Novavax"@el . . . . . . . . . . "Novavax ist ein US-amerikanisches Pharmaunternehmen, das auf die Entwicklung von Impfstoffen spezialisiert ist. Es hat seinen Hauptsitz in Gaithersburg in Maryland und zus\u00E4tzliche Einrichtungen in Rockville (Maryland) und Uppsala (Schweden). Novavax ist an der NASDAQ gelistet."@de . ""@en . . . "28401"^^ . . . . . "Novavax, Inc. \u2013 ameryka\u0144skie przedsi\u0119biorstwo biotechnologiczne za\u0142o\u017Cone w 1987 roku, z siedzib\u0105 w Gaithersburgu w stanie Maryland, notowane na nowojorskiej gie\u0142dzie NASDAQ."@pl . . "Novavax, Inc. est une soci\u00E9t\u00E9 pharmaceutique am\u00E9ricaine sp\u00E9cialis\u00E9e dans les vaccins. En ao\u00FBt 2020, elle pr\u00E9pare un vaccin contre la Covid-19, le NVX-CoV2373, pour lequel elle a re\u00E7u une pr\u00E9commande de 100 millions de doses du gouvernement am\u00E9ricain, pour un montant de 1,6 milliard de dollars. Elle re\u00E7oit aussi une commande de 200 millions de doses de l'Union europ\u00E9enne en ao\u00FBt 2021."@fr . . . "Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus (RSV), as well as Ebola and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its NVX-CoV2373 vaccine for COVID-19. Their vaccine, Nuvaxovid, was approved in the European Union at the end of 2021 and in Canada in February 2022, as the fifth vaccine against COVID-19, following Pfizer/BioNTech, Moderna, Janssen and AstraZeneca."@en . "\u8AFE\u74E6\u74E6\u514B\u65AF\u91AB\u85E5\uFF08Novavax\uFF09\u662F\u4E00\u5BB6\u7F8E\u570B\u75AB\u82D7\u7814\u767C\u516C\u53F8\uFF0C\u7E3D\u90E8\u4F4D\u65BC\u99AC\u91CC\u862D\u5DDE\u84CB\u745F\u65AF\u5821\uFF0C\u5728\u99AC\u91CC\u862D\u5DDE\u7F85\u514B\u7DAD\u723E\u548C\u745E\u5178\u70CF\u666E\u85A9\u62C9\u8A2D\u6709\u5DE5\u5EE0\u3002\u8A72\u516C\u53F8\u7814\u767C\u5B63\u7BC0\u6027\u6D41\u611F\u75AB\u82D7\u548C2019\u51A0\u72C0\u75C5\u6BD2\u75C5\u75AB\u82D7\u3002"@zh . . "Novavax"@uk . "Novavax"@fr . . . . "Novavax, Inc. \u2014 \u0430\u043C\u0435\u0440\u0438\u043A\u0430\u043D\u0441\u044C\u043A\u0430 \u043A\u043E\u043C\u043F\u0430\u043D\u0456\u044F \u0437 \u0440\u043E\u0437\u0440\u043E\u0431\u043A\u0438 \u0432\u0430\u043A\u0446\u0438\u043D \u0437\u0456 \u0448\u0442\u0430\u0431-\u043A\u0432\u0430\u0440\u0442\u0438\u0440\u043E\u044E \u0443 \u0413\u0435\u0439\u0442\u0435\u0440\u0441\u0431\u0443\u0440\u0433\u0443 \u0448\u0442\u0430\u0442 \u041C\u0435\u0440\u0456\u043B\u0435\u043D\u0434, \u0456\u0437 \u0434\u043E\u0434\u0430\u0442\u043A\u043E\u0432\u0438\u043C\u0438 \u043F\u043E\u0442\u0443\u0436\u043D\u043E\u0441\u0442\u044F\u043C\u0438 \u0443 \u0420\u043E\u043A\u0432\u0456\u043B\u0456 \u0456 \u0423\u043F\u043F\u0441\u0430\u043B\u0456."@uk . . "Novavax"@in . . . . . "Worldwide"@en . . . . . . . . . . "1541"^^ . "1.15E9"^^ . . "Novavax Inc. \u00E4r ett b\u00F6rsnoterat amerikanskt l\u00E4kemedelsf\u00F6retag, som utvecklar vacciner. Det grundades 1987 och har sitt huvudkontor i Gaithersburg i Maryland i USA och verksamhet ocks\u00E5 i Rockville i Maryland och Uppsala. Novavax k\u00F6pte 2013 det 1999\u20132000 grundade svenska l\u00E4kemedelsutvecklingsf\u00F6retaget Isconova AB i Uppsala. Novavax utvecklar NanoFlu som ett effektivare influensavaccin \u00E4n de som \u00E4r i marknaden 2020 och fick i januari 2020 \"fast track\"-tillst\u00E5nd av amerikanska Food and Drug Administration."@sv . . . "Novavax, Inc. \u2014 \u0430\u043C\u0435\u0440\u0438\u043A\u0430\u043D\u0441\u044C\u043A\u0430 \u043A\u043E\u043C\u043F\u0430\u043D\u0456\u044F \u0437 \u0440\u043E\u0437\u0440\u043E\u0431\u043A\u0438 \u0432\u0430\u043A\u0446\u0438\u043D \u0437\u0456 \u0448\u0442\u0430\u0431-\u043A\u0432\u0430\u0440\u0442\u0438\u0440\u043E\u044E \u0443 \u0413\u0435\u0439\u0442\u0435\u0440\u0441\u0431\u0443\u0440\u0433\u0443 \u0448\u0442\u0430\u0442 \u041C\u0435\u0440\u0456\u043B\u0435\u043D\u0434, \u0456\u0437 \u0434\u043E\u0434\u0430\u0442\u043A\u043E\u0432\u0438\u043C\u0438 \u043F\u043E\u0442\u0443\u0436\u043D\u043E\u0441\u0442\u044F\u043C\u0438 \u0443 \u0420\u043E\u043A\u0432\u0456\u043B\u0456 \u0456 \u0423\u043F\u043F\u0441\u0430\u043B\u0456."@uk . . "\u0646\u0648\u0641\u0627\u0641\u0627\u0643\u0633"@ar . "\uB178\uBC14\uBC31\uC2A4 \uC8FC\uC2DD\uD68C\uC0AC(Novavax, Inc.)\uB294 \uBBF8\uAD6D \uBA54\uB9B4\uB79C\uB4DC\uC8FC\uC5D0 \uBCF8\uC0AC\uB97C \uB454 \uBC31\uC2E0 \uAC1C\uBC1C \uD68C\uC0AC\uB85C, \uC2EC\uAC01\uD55C \uAC10\uC5FC\uBCD1\uC5D0 \uB300\uC751\uD558\uAE30 \uC704\uD55C \uD601\uC2E0\uC801\uC778 \uBC31\uC2E0\uC744 \uB9CC\uB4DC\uB294 \uC0DD\uBA85 \uACF5\uD559 \uD68C\uC0AC(biotechnology company)\uC774\uB2E4."@ko . . "Novavax"@it . . . . . . . "Novavax, Inc."@en . . . . "1541"^^ . . . . . . . "POINT(-77.226699829102 39.137100219727)"^^ . "Novavax, Inc. \u00E8 una societ\u00E0 di biotecnologie statunitense che si concentra sulla scoperta, lo sviluppo, la produzione e la commercializzazione di vaccini e adiuvanti per prevenire gravi malattie infettive utilizzando la sua tecnologia proprietaria di vaccini a nanoparticelle ricombinanti. I candidati al vaccino dell'azienda includono il Nuvaxovid (NVX-CoV2373), un vaccino ricombinante a subunit\u00E0 di glicoproteina SARS-CoV-2 adiuvato, contro il coronavirus che si trova in due studi di Fase III, uno di Fase IIb e uno di Fase I/II; NanoFlu, un candidato al vaccino contro l'influenza stagionale quadrivalente a nanoparticelle che \u00E8 in fase III di sperimentazione clinica; e ResVax, un candidato al vaccino con nanoparticelle proteiche di fusione (F) del virus respiratorio sinciziale umano (hRSV) attualmente in sperimentazione clinica di Fase III, in Fase II per gli anziani (60 anni e oltre) e in Fase I per la pediatria. Inoltre, l'azienda sviluppa vaccini candidati per la protezione contro la sindrome respiratoria mediorientale (MERS) (in fase di studio preclinico in associazione alla sindrome respiratoria acuta grave) e un candidato al vaccino a glicoproteina del virus ebola. Novavax ha un accordo di collaborazione con la multinazionale farmaceutica Takeda Pharmaceutical Co. per lo sviluppo, la produzione e la commercializzazione giapponese di NVX-CoV2373, il candidato al vaccino anti COVID-19. Costituita nel 1987 con sede a Gaithersburg, nel Maryland, \u00E8 inserita nell\u2019indice Russell 2000 e quotata al Nasdaq."@it . . . "6.70002401E9"^^ . . "\u8AFE\u74E6\u74E6\u514B\u65AF\u91AB\u85E5\uFF08Novavax\uFF09\u662F\u4E00\u5BB6\u7F8E\u570B\u75AB\u82D7\u7814\u767C\u516C\u53F8\uFF0C\u7E3D\u90E8\u4F4D\u65BC\u99AC\u91CC\u862D\u5DDE\u84CB\u745F\u65AF\u5821\uFF0C\u5728\u99AC\u91CC\u862D\u5DDE\u7F85\u514B\u7DAD\u723E\u548C\u745E\u5178\u70CF\u666E\u85A9\u62C9\u8A2D\u6709\u5DE5\u5EE0\u3002\u8A72\u516C\u53F8\u7814\u767C\u5B63\u7BC0\u6027\u6D41\u611F\u75AB\u82D7\u548C2019\u51A0\u72C0\u75C5\u6BD2\u75C5\u75AB\u82D7\u3002"@zh . . . . . . "Novavax, Inc. es una compa\u00F1\u00EDa estadounidense de desarrollo de vacunas con sede en Gaithersburg, Maryland, con instalaciones adicionales en Rockville, Maryland, y Upsala, Suecia. A partir de 2020 realiza un ensayo cl\u00EDnico en curso, de fase III, en adultos mayores para su vacuna candidata para la gripe estacional, NanoFlu, y una vacuna candidata para la prevenci\u00F3n de COVID-19. En febrero de 2021 ten\u00EDa una vacuna candidata para COVID-19, NVX-CoV2373, en pruebas cl\u00EDnicas de fase 3 y que desde el 12 de febrero est\u00E1 siendo revisada en forma continua por la Agencia Europea del Medicamento.\u200B\u200B\u200B"@es . "Novavax-logo.svg"@en . . . "Novavax Inc. \u00E4r ett b\u00F6rsnoterat amerikanskt l\u00E4kemedelsf\u00F6retag, som utvecklar vacciner. Det grundades 1987 och har sitt huvudkontor i Gaithersburg i Maryland i USA och verksamhet ocks\u00E5 i Rockville i Maryland och Uppsala. Novavax k\u00F6pte 2013 det 1999\u20132000 grundade svenska l\u00E4kemedelsutvecklingsf\u00F6retaget Isconova AB i Uppsala. Novavax utvecklar NanoFlu som ett effektivare influensavaccin \u00E4n de som \u00E4r i marknaden 2020 och fick i januari 2020 \"fast track\"-tillst\u00E5nd av amerikanska Food and Drug Administration."@sv . "Novavax, Inc. es una compa\u00F1\u00EDa estadounidense de desarrollo de vacunas con sede en Gaithersburg, Maryland, con instalaciones adicionales en Rockville, Maryland, y Upsala, Suecia. A partir de 2020 realiza un ensayo cl\u00EDnico en curso, de fase III, en adultos mayores para su vacuna candidata para la gripe estacional, NanoFlu, y una vacuna candidata para la prevenci\u00F3n de COVID-19. La compa\u00F1\u00EDa posiciona a NanoFlu por la necesidad insatisfecha de una vacuna m\u00E1s efectiva contra la influenza, particularmente en los ancianos que a menudo sufren complicaciones graves[cita requerida] y a veces potencialmente mortales. En enero de 2020, la Administraci\u00F3n de Alimentos y Medicamentos de los Estados Unidos (FDA) le otorg\u00F3 el estado de v\u00EDa r\u00E1pida para NanoFlu. En febrero de 2021 ten\u00EDa una vacuna candidata para COVID-19, NVX-CoV2373, en pruebas cl\u00EDnicas de fase 3 y que desde el 12 de febrero est\u00E1 siendo revisada en forma continua por la Agencia Europea del Medicamento.\u200B\u200B\u200B"@es . . "Novavax, Inc. \u00E8 una societ\u00E0 di biotecnologie statunitense che si concentra sulla scoperta, lo sviluppo, la produzione e la commercializzazione di vaccini e adiuvanti per prevenire gravi malattie infettive utilizzando la sua tecnologia proprietaria di vaccini a nanoparticelle ricombinanti. Novavax ha un accordo di collaborazione con la multinazionale farmaceutica Takeda Pharmaceutical Co. per lo sviluppo, la produzione e la commercializzazione giapponese di NVX-CoV2373, il candidato al vaccino anti COVID-19."@it . "Novavax"@es . . "Novavax research and development laboratories in Gaithersburg"@en . . "Novavax, Inc. est une soci\u00E9t\u00E9 pharmaceutique am\u00E9ricaine sp\u00E9cialis\u00E9e dans les vaccins. En ao\u00FBt 2020, elle pr\u00E9pare un vaccin contre la Covid-19, le NVX-CoV2373, pour lequel elle a re\u00E7u une pr\u00E9commande de 100 millions de doses du gouvernement am\u00E9ricain, pour un montant de 1,6 milliard de dollars. Elle re\u00E7oit aussi une commande de 200 millions de doses de l'Union europ\u00E9enne en ao\u00FBt 2021."@fr . "Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus (RSV), as well as Ebola and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its NVX-CoV2373 vaccine for COVID-19."@en . . . . . . "Novavax"@sv . . "1111861641"^^ . . . . . "Novavax, Inc. je americk\u00FD v\u00FDrobce vakc\u00EDn. Spole\u010Dnost byla zalo\u017Eena v roce 1987 a s\u00EDdl\u00ED ve m\u011Bst\u011B ve st\u00E1t\u011B Maryland. Gener\u00E1ln\u00EDm \u0159editelem je . Novavax m\u00E1 791 zam\u011Bstnanc\u016F. Firma obdr\u017Eela grant ve v\u00FD\u0161i 82,553,834 dolar\u016F od Nadace Billa a Melindy Gatesov\u00FDch. V roce 2013 se stala majetkem spole\u010Dnosti tov\u00E1rna Isconova AB (dnes Novavax AB) ve \u0161v\u00E9dsk\u00E9 Uppsale. V roce 2020 firma zakoupila provoz v Bohumili u Prahy (spole\u010Dnost Praha Vaccines a. s., dnes Novavax CZ a. s.)."@cs . . . "Novavax"@ca . . . . "Novavax, Inc. \u2013 ameryka\u0144skie przedsi\u0119biorstwo biotechnologiczne za\u0142o\u017Cone w 1987 roku, z siedzib\u0105 w Gaithersburgu w stanie Maryland, notowane na nowojorskiej gie\u0142dzie NASDAQ."@pl . . . . . . . . . "Novavax"@pl . . . . . . . "1987"^^ . . "Novavax, Inc."@en . . . . . . "1.15E9"^^ . . . . . . . . . . . "\u0646\u0648\u0641\u0627\u0641\u0627\u0643\u0633 (\u0628\u0627\u0644\u0625\u0646\u062C\u0644\u064A\u0632\u064A\u0629: Novavax)\u200F \u0647\u064A \u0634\u0631\u0643\u0629 \u0623\u0645\u0631\u064A\u0643\u064A\u0629 \u062A\u0642\u0648\u0645 \u0628\u062A\u0637\u0648\u064A\u0631 \u0644\u0642\u0627\u062D\u0627\u062A \u0636\u062F \u0627\u0644\u0623\u0645\u0631\u0627\u0636.\u064A\u0642\u0639 \u0645\u0642\u0631\u0647\u0627 \u0627\u0644\u0631\u0626\u064A\u0633\u064A \u0641\u064A \u063A\u0627\u064A\u062B\u0631\u0633\u0628\u064A\u0631\u063A \u060C\u0645\u064A\u0631\u064A\u0644\u0627\u0646\u062F \u0648\u062A\u0645\u062A\u0644\u0643 \u0645\u0646\u0634\u0622\u062A \u0641\u064A \u0645\u062F\u064A\u0646\u0629 \u0631\u0648\u0643\u0641\u064A\u0644 \u0648\u0645\u062F\u064A\u0646\u0629 \u0623\u0648\u0628\u0633\u0627\u0644\u0627 \u0641\u064A \u0627\u0644\u0633\u0648\u064A\u062F."@ar . . . . . "42631881"^^ . "Novavax, Inc. je americk\u00FD v\u00FDrobce vakc\u00EDn. Spole\u010Dnost byla zalo\u017Eena v roce 1987 a s\u00EDdl\u00ED ve m\u011Bst\u011B ve st\u00E1t\u011B Maryland. Gener\u00E1ln\u00EDm \u0159editelem je . Novavax m\u00E1 791 zam\u011Bstnanc\u016F. Firma obdr\u017Eela grant ve v\u00FD\u0161i 82,553,834 dolar\u016F od Nadace Billa a Melindy Gatesov\u00FDch. V roce 2013 se stala majetkem spole\u010Dnosti tov\u00E1rna Isconova AB (dnes Novavax AB) ve \u0161v\u00E9dsk\u00E9 Uppsale. V roce 2020 firma zakoupila provoz v Bohumili u Prahy (spole\u010Dnost Praha Vaccines a. s., dnes Novavax CZ a. s.). Jedn\u00EDm z produkt\u016F je vakc\u00EDna proti ch\u0159ipce . Novavax vyrobil tak\u00E9 vakc\u00EDnu NVX-CoV2373 proti nemoci covid-19. V b\u0159eznu 2021 byly zve\u0159ejn\u011Bny v\u00FDsledky test\u016F, podle nich\u017E m\u00E1 tento prepar\u00E1t \u00FA\u010Dinnost 96 procent. Po schv\u00E1len\u00ED se pl\u00E1nuje produkce a\u017E miliardy d\u00E1vek ro\u010Dn\u011B."@cs . "1000694"^^ . "2022"^^ . "Novavax"@de . . "-77.22669982910156"^^ . . . . . "Novavax, Inc. adalah sebuah perusahaan pengembangan vaksin Amerika Serikat yang bermarkas besar di Gaithersburg, Maryland, dengan fasilitas-fasilitas tambahan di Rockville, Maryland dan Uppsala, Swedia. Pada 2020, perusahaan tersebut menjalani pengujian klinis Tahap III terhadap orang-orang dewasa untuk vaksin kandidatnya untuk , NanoFlu dan vaksin kandidat untuk pencegahan COVID-19."@in . . . . "39.13710021972656"^^ . "39.1371 -77.2267" . . . . . . . .